NCT07737171Recruiting

Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions

The University of Texas Health Science Center, Houston

Start Date

4/7/2026

Completion Date

4/1/2033

Summary

This is a 7-year prospective single-center registry study to assess the safety and efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the treatment of pancreatic lesions.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Diagnosis of any pancreatic pre-malignant lesion and/or pancreatic malignancy * Patients already undergoing EUS-RFA for treatment of pancreatic lesions clinically Exclusion Criteria: * Patients with co-existing malignancies of other organs (or a prior history of such) * Patients unable to provide informed consent * Patients unable to complete follow-up

Interventions

DEVICE

Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA)

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Pancreatic Cancer

Locations

The University of Texas Health Science Center at Houston

Houston, Texas 77030

United States

Run studies, or work at a research site?

Corterve helps sites and sponsors reach patients who are looking for trials. It does not determine eligibility and does not promise an enrolment outcome.

For sponsors, CROs and sites

What Corterve sells to organisations, and the anti-kickback constraints it works within.

Services and published prices

Lay summaries for EU CTR Annex V, pre-screen filtration, recruitment-creative regulatory operations, feasibility reporting.

For research sites

One published licence rate, the same for every site, and the fees a site is never charged.